John Sheridan

ATLANTA (July 20, 2026) – The Arthritis Foundation and the Childhood Arthritis and Rheumatology Research Alliance (CARRA) today announced grants – totaling nearly $2 million – to support physician-led research in pediatric rheumatology. CARRA-Arthritis Foundation Grant Program awards for 2026 will fund research in juvenile idiopathic arthritis (JIA), pediatric lupus, juvenile dermatomyositis, childhood vasculitis, autoimmune brain disease, and …

We are excited to share that CARRA and the Pediatric Rheumatology Collaborative Study Group (PRCSG) have collaborated to initiate the convening and planning of an FDA Workshop: Accelerating Product Development for Pediatric Systemic Lupus Erythematosus (SLE). This forum provides an opportunity for the broader community to discuss ways to streamline drug development and ensure that our community’s …

Washington, DC, (APRIL 17, 2026) – The Childhood Arthritis and Rheumatology Research Alliance (CARRA) is proud to announce the winners of the 2026 CARRA Community Awards. The awards, which were presented at CARRA’s Annual Scientific Meeting this month, honor people who have made outstanding achievements in advancing pediatric rheumatology research and played important roles in …

WASHINGTON, D.C., October 3, 2025 – There are new long-term results from a landmark study using the CARRA Registry that looks at when to start biologics in children diagnosed with Polyarticular Juvenile Idiopathic Arthritis (poly JIA) comparing the CARRA Consensus Treatment Plans (CTPs). After following nearly 300 children with poly JIA in the CARRA Registry for …

ATLANTA (July 14, 2025) —  In response to changes in the federal funding environment, the Arthritis Foundation and the Childhood Arthritis and Rheumatology Research Alliance (CARRA) have increased funding for their joint grant program that supports physician-led research in pediatric rheumatology. This year, the CARRA-Arthritis Foundation Grant Program will award nearly $2 million – an …

The Childhood Arthritis and Rheumatology Research Alliance (CARRA) has named Rachel Myslinski, MBA, as Chief Executive Officer (CEO). Myslinski is a senior executive with more than 20 years of experience in healthcare in the professional medical association, management consulting, and non-profit research foundation settings. She brings deep expertise in executive leadership, strategic planning, non-profit Board …

Use of Extrapolation to Support Regulatory Decision-Making Discussed (Washington, DC – August 4, 2023) – Findings from a recent stakeholder workshop on the development of therapeutics for polyarticular JIA (pJIA) were published online in the April 27, 2023 issue of Arthritis & Rheumatology. The report, “Therapeutic Development in Polyarticular Course Juvenile Idiopathic Arthritis (pcJIA): Extrapolation, …

The Arthritis Foundation and the Childhood Arthritis and Rheumatology Research Alliance (CARRA) announce the recipients of almost $1.2 million in research funding for pediatric rheumatic diseases. Read the full press release at arthritis.org.

WASHINGTON, DC, December 6, 2022 – The Childhood Arthritis and Rheumatology Research Alliance, also known as CARRA, announced the appointment of Mathieu Nelessen as Chief Executive Officer, effective January 9, 2023. The CARRA Board of Directors unanimously approved the recommendation of Mr. Nelessen by a CARRA CEO search task force, which led a three-month nationwide …